The new plant will manufacture and distribute insulin, a diabetes product.
The plant is expected to produce nearly 1,500kg/y of insulin or around 45m vials.
Julphar also said based on the demand, the production at the plant will be increased.
The company was quoted by Construction Week Online as saying that some 20% of the Gulf’s population now has diabetes with the number likely to double by 2030 if action is not taken to contain the disease.
The company at present manufactures insulin from its in-house made crystals, while the same 8 years ago were produced using European crystals.
Julphar expects increased market for insulin over the next few years.